期刊文献+

造影剂肾病临床研究 被引量:4

下载PDF
导出
摘要 目的探讨造影剂肾病患者的临床特点,为今后临床预防和治疗工作提供可靠的参考依据。方法抽取2010年1月—2012年5月间我院收治的行冠脉造影和冠脉干预患者319例作为研究对象,统计造影剂肾病发生率,并对比分析不同危险程度患者造影剂肾病发生率以及造影剂肾病患者和非造影剂肾病患者生化指标检测结果。结果 319例患者中共有33例患者发生造影剂肾病,且随着患者危险程度的增加造影剂肾病的发生率逐渐升高(P<0.05);造影剂肾病患者与非造影剂肾病患者血红蛋白水平、红细胞压积以及低密度脂蛋白(LDL)水平均存在明显差异(P<0.05),而肌酐、血磷、血钙水平差异无统计学意义(P>0.05)。结论在对患者行冠脉造影时应密切观察是否会引起造影剂肾病,采取积极有效的措施对高危患者展开预防,可以有效降低造影剂肾病发生率。
机构地区 武威市凉州医院
出处 《基层医学论坛》 2013年第25期3333-3334,共2页 The Medical Forum
  • 相关文献

参考文献5

二级参考文献66

  • 1邹古明,颜红兵.造影剂肾病的诊断与治疗现状[J].中国介入心脏病学杂志,2005,13(3):194-196. 被引量:78
  • 2赵景宏,黄岚.造影剂肾病及预防措施的研究进展[J].重庆医学,2007,36(1):87-89. 被引量:15
  • 3Berg KJ.Nephrotoxicity related to contrast media.Scand J Urel Nephrol,2000,34:317-322.
  • 4Aspelin P,Aubry P,Fransson SG,et el.Nephrotoxic effects in patients undergoing angiography.N Engl[J] Med,2003,348:491-499.
  • 5Best PJ,Lennon R,Ting HH,et el.The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions.[J] Am Coil Cardio1,2002,39:1113-1119.
  • 6McCullough PA,Wolyn R,Rocher LL,et al.Acute renal failure after coronary intervention,risk factors and relationship to mortality.Am J Med,1997,103:368-375.
  • 7Ruddy MC.Angiotensin Ⅱ receptor block in diabetic nephropathy[J].Am J Hyperens,2002,15:468-471.
  • 8Goldenberg I,Matetzky S.Nephropathy induced by contrast media pathogenesis,risk factors and preventive strategies[J].CMA J,2005,172 (11):1461-1471.
  • 9Haeussler U,Riedei M,Keller F.Free reacrive oxygen species and nephrotoxicity of contrast agents[J].Kidney Blood Press Res,2004,27 (3):167-171.
  • 10Murphy S W,Barrett B J,Parfrey P S.Contrast nephropathy[J].J Am Soc Nephrol,2000,11 (1):177-182.

共引文献57

同被引文献40

  • 1姜文兵,傅国胜.造影剂肾病预防的研究进展[J].临床荟萃,2006,21(12):897-900. 被引量:23
  • 2Golshahi J, Nasri H, Gharipour M. Contrast-induced nephropathy : A literature review[J]. J Nephropathol, 2014,3 (2) 51-56.
  • 3Tehrani S, Laing C, Yellon DM, et al. Contrast-induced acute kidney injury following PCI[J]. Eur J Clin Invest, 2013,43 (5) :483-490.
  • 4Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy trial[J]. Am J Cardiol,2011,108(1) : 1-7.
  • 5陈涛,张杰.胱抑素C在心血管病学中的研究进展[J].中华临床医师杂志:电子版,2013,7(10):4481-4484.
  • 6CheUo M,Goffredo C,Patti G,Effects of atorvasatin on arterial endothelial function in co ronary bypass surgery[J].Eur J Cardiothorac Surg,2005,28(6):805-810.
  • 7Rudnick MR,Goldfarb S.Pathogenesis of contrast- induced nephropathy: experimental clinical observations with all emphasis on the role of osmolality [J].Rev Cardiovasc Med,2003,4(5):28-33.
  • 8Patti G,Nusca A,CheNo M,et al.Usefulness of statin pretreatment to prevent contrast-in dueed nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention [J].Am J Cardiol,2008,101(3):279-285.
  • 9Gandhi S,Mosleh W, Abdel-Qadir H, et al.Statins and contrast-induced acute kidney injury with coronary angiography [J].Am J Cardiol,2014,27(10):987-1000.
  • 10高勇莉,曾晓霞,安健,李保.造影剂肾病的预防及护理[J].护理研究(上旬版),2009,23(1):15-16. 被引量:26

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部